Glenmark Pharmaceuticals Gestione
Gestione criteri di controllo 1/4
Glenmark Pharmaceuticals Il CEO è Glenn Saldanha, nominato in Jan2001, e ha un mandato di 23.83 anni. la retribuzione annua totale è ₹ 168.61M, composta da 80% di stipendio e 20% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.35% delle azioni della società, per un valore di ₹ 1.47B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 6.5 anni.
Informazioni chiave
Glenn Saldanha
Amministratore delegato
₹168.6m
Compenso totale
| Percentuale dello stipendio del CEO | 80.0% |
| Mandato del CEO | 23.8yrs |
| Proprietà del CEO | 0.4% |
| Durata media del management | 1.5yrs |
| Durata media del Consiglio di amministrazione | 6.5yrs |
Aggiornamenti recenti sulla gestione
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Recent updates
Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now
Oct 26This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50
Sep 06Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -₹10b |
| Jun 30 2024 | n/a | n/a | -₹16b |
| Mar 31 2024 | ₹169m | ₹135m | -₹19b |
| Dec 31 2023 | n/a | n/a | -₹8b |
| Sep 30 2023 | n/a | n/a | -₹1b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹162m | ₹130m | -₹2b |
| Dec 31 2022 | n/a | n/a | ₹9b |
| Sep 30 2022 | n/a | n/a | ₹8b |
| Jun 30 2022 | n/a | n/a | ₹8b |
| Mar 31 2022 | ₹158m | ₹130m | ₹9b |
| Dec 31 2021 | n/a | n/a | ₹10b |
| Sep 30 2021 | n/a | n/a | ₹10b |
| Jun 30 2021 | n/a | n/a | ₹10b |
| Mar 31 2021 | ₹139m | ₹110m | ₹10b |
| Dec 31 2020 | n/a | n/a | ₹10b |
| Sep 30 2020 | n/a | n/a | ₹9b |
| Jun 30 2020 | n/a | n/a | ₹9b |
| Mar 31 2020 | ₹122m | ₹91m | ₹8b |
| Dec 31 2019 | n/a | n/a | ₹7b |
| Sep 30 2019 | n/a | n/a | ₹6b |
| Jun 30 2019 | n/a | n/a | ₹8b |
| Mar 31 2019 | ₹157m | ₹131m | ₹9b |
| Dec 31 2018 | n/a | n/a | ₹9b |
| Sep 30 2018 | n/a | n/a | ₹9b |
| Jun 30 2018 | n/a | n/a | ₹7b |
| Mar 31 2018 | ₹162m | ₹134m | ₹8b |
Compensazione vs Mercato: La retribuzione totale di Glenn ($USD 2.00M ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 779.44K ).
Compensazione vs guadagni: La retribuzione di Glenn è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Glenn Saldanha (54 yo)
23.8yrs
Mandato
₹168,610,000
Compensazione
Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Limited since 2000. Mr. Saldanha serves as Chairman at Ichnos Sciences Inc. Mr. Saldanha serv...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 23.8yrs | ₹168.61m | 0.35% ₹ 1.5b | |
| Executive Director of Corporate Services & Executive Director | no data | ₹60.84m | 0.27% ₹ 1.1b | |
| Executive Director | less than a year | ₹102.12m | Nessun dato | |
| Company Secretary & Compliance Officer | 7.8yrs | ₹5.53m | Nessun dato | |
| President and Chief Human Resources Officer | 2.8yrs | Nessun dato | Nessun dato | |
| President & Head of Global Pharmaceutical Development | 2.2yrs | Nessun dato | Nessun dato | |
| President & Chief Quality Officer | 1.2yrs | Nessun dato | Nessun dato | |
| President & Global Head of Formulation Operations | 1.2yrs | Nessun dato | Nessun dato | |
| President & Business Head of India Formulations | 1.3yrs | Nessun dato | Nessun dato | |
| President and Business Head of Europe & Emerging Markets | 1.8yrs | Nessun dato | Nessun dato | |
| President & Business Head of North America | less than a year | Nessun dato | Nessun dato | |
| Investor Relations Officer | no data | Nessun dato | Nessun dato |
1.5yrs
Durata media
55yo
Età media
Gestione esperta: Il team dirigenziale di GLENMARK non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 26.1yrs | ₹168.61m | 0.35% ₹ 1.5b | |
| Executive Director of Corporate Services & Executive Director | 25.1yrs | ₹60.84m | 0.27% ₹ 1.1b | |
| Executive Director | 6.5yrs | ₹102.12m | Nessun dato | |
| President | less than a year | Nessun dato | Nessun dato | |
| Non Executive Director | 19.3yrs | ₹600.00k | 0.39% ₹ 1.6b | |
| Non-Executive Independent Director | 22.5yrs | ₹1.90m | 0.039% ₹ 161.4m | |
| Independent Non-Executive Director | 1.8yrs | ₹1.20m | Nessun dato | |
| Independent Non-Executive Director | 4.3yrs | ₹1.10m | Nessun dato | |
| Independent Non-Executive Director | 5.6yrs | ₹1.40m | Nessun dato |
6.5yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GLENMARK sono considerati esperti (durata media dell'incarico 6.5 anni).